A new tumor biomarker: Serum protein peak at 3144 m/z in patients with node-positive breast cancer.
e22050 Background: To explore the association of the 3144 m/z and the clinicopathological features and its clinical value in the diagnosis and prognosis of breast cancer. Methods: Using SELDI-TOF-MS, we analyzed serum 3144 m/z in 298 patients patients with node-positive breast cancer after mastectomy. The association between 3144 m/z and clinicopathological features was evaluated. We also evaluated their prognosis value in survival using univariable and multivariable statistical analyses. Results: The positive rate was higher in 3144 m/z than CA153 (36.6% versus 11.5%, p <0.001). The 3144 m/z positive rate was no difference in patients with CA153 negative or positive (35.3% versus 29.6%, P =0.563). 3144 m/z was higher elder cases (> 50 years old) than young group(<or=50 years old). There were no correlation was found between 3144 m/z and other clinicopathological features, except for the age (42.8% in > 50-year-old and 31.2% in young,χ2=4.227, P=0.040). The patients with 3144m/z negative (n=189) had higher 3-year OS rate than positive (n=109), 89.5% versus 81.7% (P=0.034). Also in young (P=0.024), postmenopasual (P=0.025), small tumor (P<0.001), node(-) or less (P<0.001), early stage (P<0.001), good molecular type (P=0.019), normal CA153 (P<0.001), neoadjuvant chemotherapy (P=0.001). Using Cox proportional hazards model,analysis showed that basal-like type (worse, P=0.038), CA153 positive (worse, P=0.015), adjuvant chemotherapy (better, P=0.028) and adjuvant radiotherapy (better, P=0.032) were independent prognostic factors in patients with node-positive breast cancer. but the 3144m/z was not. Conclusions: Serum protein peak at 3144 m/z provides a new, practical biomarker for diagnosis and prognosis of breast cancer.